Cargando…

Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis

The PP2A signaling axis regulates multiple oncogenic drivers of castration resistant prostate cancer (CRPC). We show that targeting the endogenous PP2A regulator, SET (I2PP2A), is a viable strategy to inhibit prostate cancers that are resistant to androgen deprivation therapy. Our data is corroborat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Xiaoyong, Garcia, Consuelo, Fazli, Ladan, Gleave, Martin, Vitek, Michael P., Jansen, Marilyn, Christensen, Dale, Mulholland, David J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643319/ https://www.ncbi.nlm.nih.gov/pubmed/26563471 http://dx.doi.org/10.1038/srep15182

Ejemplares similares

Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass
por: Yang, Chih-Cheng, et al.
Publicado: (2015)

Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity
por: Cherif, Chaïma, et al.
Publicado: (2021)

High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics
por: Kesch, Claudia, et al.
Publicado: (2021)

Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer
por: Ozturk, Sait, et al.
Publicado: (2020)

Analytic Validation of a Clinical-Grade PTEN Immunohistochemistry Assay in Prostate Cancer by Comparison to PTEN FISH
por: Lotan, Tamara L., et al.
Publicado: (2016)

Targeting the adaptive molecular landscape of castration-resistant prostate cancer
por: Wyatt, Alexander W, et al.
Publicado: (2015)

Targeting SET/I(2)PP2A Oncoprotein Functions as a Multi-pathway Strategy for Cancer Therapy
por: Switzer, Christopher H., et al.
Publicado: (2011)

Novel non-AR therapeutic targets in castrate resistant prostate cancer
por: Toren, Paul J., et al.
Publicado: (2013)

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
por: Turnham, Daniel J., et al.
Publicado: (2020)

c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer
por: Maina, Peterson Kariuki, et al.
Publicado: (2016)

Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model
por: Liang, Mengmeng, et al.
Publicado: (2015)

Long term deficiency of vitamin D in germ cell testicular cancer survivors
por: Nappi, Lucia, et al.
Publicado: (2018)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

PP2A methylesterase PME‐1 suppresses anoikis and is associated with therapy relapse of PTEN ‐deficient prostate cancers
por: Aakula, Anna, et al.
Publicado: (2023)

Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival
por: Fan, Lingling, et al.
Publicado: (2015)

Correction: Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model
por: Liang, Mengmeng, et al.
Publicado: (2016)

A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss
por: Myint, Zin W., et al.
Publicado: (2021)

World Trade Center Dust Exposure Promotes Cancer in PTEN-deficient Mouse Prostates
por: Wang, Lin, et al.
Publicado: (2022)

Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene
por: Luo, Jindan, et al.
Publicado: (2019)

20(S)-protopanaxadiol regio-selectively targets androgen receptor: anticancer effects in castration-resistant prostate tumors
por: Ben-Eltriki, Mohamed, et al.
Publicado: (2018)

A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer
por: Troyer, Dean A, et al.
Publicado: (2015)

Anti-Tumor Effects of Ginsenoside 20(S)-Protopanaxadiol and 1,25-Dihydroxyvitamin D3 Combination in Castration Resistant Prostate Cancer
por: Ben-Eltriki, Mohamed, et al.
Publicado: (2021)

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2015)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

GATA2 as a potential metastasis-driving gene in prostate cancer
por: Chiang, Yan Ting, et al.
Publicado: (2014)

BIRC6 Protein, an Inhibitor of Apoptosis: Role in Survival of Human Prostate Cancer Cells
por: Low, Christopher G., et al.
Publicado: (2013)

Prostate Stromal Cells Express the Progesterone Receptor to Control Cancer Cell Mobility
por: Yu, Yue, et al.
Publicado: (2014)

Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
por: Watahiki, Akira, et al.
Publicado: (2013)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer
por: Cao, Subing, et al.
Publicado: (2019)

Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report
por: Julka, Pramod Kumar, et al.
Publicado: (2020)

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
por: Kmak, Jamie A., et al.
Publicado: (2020)

The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis
por: Iris Luk, Sze Ue, et al.
Publicado: (2014)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis
por: Al Nakouzi, Nader, et al.
Publicado: (2016)

Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen
por: Blumenstein, Brent, et al.
Publicado: (2013)

Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells
por: Fan, Lingling, et al.
Publicado: (2020)

Withaferin A Inhibits Prostate Carcinogenesis in a PTEN-deficient Mouse Model of Prostate Cancer()()
por: Moselhy, Jim, et al.
Publicado: (2017)

Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer
por: Wang, Lei, et al.
Publicado: (2016)

Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy
por: Blute, Michael L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4oju54l3tvfjfmslfn2jtv8psj